Metsystem ApSAktiv

CVR 43833642

Økonomiske nøgletal

-1.350.064 kr.-29,9%
Bruttofortjeneste 2025
-1,5 mio.-1 mio.-500 t.020242025

Nøgletal

2025
Balancens sammensætning
OmsætningsaktiverAnlægsaktiverGæld og hensatte forpligtelserEgenkapital
010 mio.20 mio.20242025

Selskabsskat

indkomstår 2024
2024Skattepligtig indkomst -2.563.195 kr.0 kr.
2023Skattepligtig indkomst -116.767 kr.0 kr.
Selskabsskat →

Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk

Regnskabstal2024–2025
20242025
Balance — aktiver
Likvide beholdninger5.691.340262.162
Omsætningsaktiver i alt6.527.1121.928.276
Anlægsaktiver i alt815.440209.610
Aktiver i alt7.342.5522.137.886
Balance — passiver
Kortfristede gældsforpligtelser925.246448.908
Langfristede gældsforpligtelser14.612.12115.466.241
Gældsforpligtelser i alt15.537.36715.915.149
Selskabskapital40.00040.000
Overført resultat-8.234.815-13.817.263
Årets resultat-3.023.088-5.582.448
Egenkapital i alt-8.194.815-13.777.263
Resultatopgørelse
Bruttofortjeneste-1.039.420-1.350.064
Resultat af primær drift-3.285.164-5.735.873
EBITDA-3.280.704-5.682.356
Resultat før skat-3.575.401-6.562.653
Årets resultat-3.023.088-5.582.448
Personaleomkostninger2.241.2844.332.292
Af- og nedskrivninger4.46053.517
Andre nøgletal
Ansatte78

En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.

Om virksomheden

Årsrapport 2025

Business reviewThe company's object is to engage in research and development relating to the prognosis for the recurrence and/or metastasis of cancer, and the response to therapy through personalized medicine, as well as other activities related thereto.

Financial review The company's income statement for the year ended 31 December 2025 shows a loss of DKK 5.582.448, and the balance sheet at 31 December 2025 shows negative equity of DKK 13.777.263.The company has changed its financial year last year. The comparative figures cover the period from 1 July 2024 to 31 December 2024 and covers only 6 months and are therefore not directly comparable. The Company has lost its entire share capital. Despite this capital loss, Management assesses that the Company continues to have a sufficient capital base and liquidity to support ongoing operations. Management continuously monitors the capital structure and the potential need to re-establish equity. Management is actively working to secure additional funding during the financial year 2026. With the grants and loans already secured, the Company has the financial resources and liquidity to carry out its planned activities for the next 12 months.

Uddrag af ledelsesberetningen i den seneste årsrapport.

Metsystem ApS — cvrprofil.dk